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Summary
Background Late-stage isolated medial knee osteoarthritis can be treated with total knee replacement (TKR) or partial 
knee replacement (PKR). There is high variation in treatment choice and little robust evidence to guide selection. The 
Total or Partial Knee Arthroplasty Trial (TOPKAT) therefore aims to assess the clinical effectiveness and cost-
effectiveness of TKR versus PKR in patients with medial compartment osteoarthritis of the knee, and this represents 
an analysis of the main endpoints at 5 years.
Methods Our multicentre, pragmatic randomised controlled trial was done at 27 UK sites. We used a combined 
expertise-based and equipoise-based approach, in which patients with isolated osteoarthritis of the medial 
compartment of the knee and who satisfied general requirements for a medial PKR were randomly assigned (1:1) to 
receive PKR or TKR by surgeons who were either expert in and willing to perform both surgeries or by a surgeon with 
particular expertise in the allocated procedure. The primary endpoint was the Oxford Knee Score (OKS) 5 years after 
randomisation in all patients assigned to groups. Health-care costs (in UK 2017 prices) and cost-effectiveness were 
also assessed. This trial is registered with ISRCTN (ISRCTN03013488) and ClinicalTrials.gov (NCT01352247).
Findings Between Jan 18, 2010, and Sept 30, 2013, we assessed 962 patients for their eligibility, of whom 
431 (45%) patients were excluded (121 [13%] patients did not meet the inclusion criteria and 310 [32%] patients 
declined to participate) and 528 (55%) patients were randomly assigned to groups. 94% of participants responded to 
the follow-up survey 5 years after their operation. At the 5-year follow-up, we found no difference in OKS between 
groups (mean difference 1·04, 95% CI –0·42 to 2·50; p=0·159). In our within-trial cost-effectiveness analysis, we 
found that PKR was more effective (0·240 additional quality-adjusted life-years, 95% CI 0·046 to 0·434) and less 
expensive (–£910, 95% CI –1503 to –317) than TKR during the 5 years of follow-up. This finding was a result of 
slightly better outcomes, lower costs of surgery, and lower follow-up health-care costs with PKR than TKR.
Interpretation Both TKR and PKR are effective, offer similar clinical outcomes, and result in a similar incidence of 
re-operations and complications. Based on our clinical findings, and results regarding the lower costs and better cost-
effectiveness with PKR during the 5-year study period, we suggest that PKR should be considered the first choice for 
patients with late-stage isolated medial compartment osteoarthritis. 
Funding National Institute for Health Research Health Technology Assessment Programme.
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Introduction
Knee replacement for osteoarthritis of the knee is an 
effective, common procedure:1,2 between 2015 and 2017, 
303 960 knee replacements were performed in the UK.1 
There are two main surgical options for late-stage 
medial compartment osteoarthritis of the knee: a 
partial knee replacement (PKR; otherwise known as a 
unicompartmental knee replacement), in which only the 
damaged compartment of the knee is replaced, or a total 
knee replacement (TKR).2 There is often disagreement 
between surgeons regarding the best choice of implant 
and the best decision for these patients, who often have 
identical pathology,3 which has led to variation in 
provision. Although fewer than 9% of knee replace-
ments in the UK are partial,1 it is estimated that up to 
47% of patients requiring knee replacements only have 
uni compartmental disease and are suitable for a PKR.4 
The best treatment option remains uncertain because 
there is little level 1 evidence to inform the clinical 
effectiveness and cost-effectiveness of either manage-
ment approach.
The existing related medical literature comprises 
four small randomised studies,5–9 individual cohort 
studies,10,11 indirect comparisons,12 and retrospective 
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studies,13–16 often examining very specific aspects of each 
procedure. To our knowledge, no one has undertaken a 
large, adequately powered, multicentre randomised 
controlled trial with long-term follow-up of patient-
reported outcomes, re-operation, or revision, to directly 
compare PKR with TKR. A revision procedure is a 
subsequent further operation to replace the original 
implant with a new device, usually because of device 
failure, infection, or persistent pain. Revision is often 
described in terms of implant survival, and it can be 
done at any time from initial implantation (in some 
cases up to 30 or 40 years after primary arthroplasty) but 
early revision (before 5 years) is considered an early 
failure of the original surgical intervention. It is 
therefore an important metric in arthroplasty outcome. 
Re-operations are any further or subsequent operation, 
which can be revision surgery or other kinds of surgery. 
Systematic reviews17,18 and unadjusted data from national 
registries1 show more frequent revision associated with 
PKR: the chance of revision with PKR is more than 
double that with a TKR. When comparing matched 
patients receiving PKRs and TKRs 8 years after the 
operations, higher frequencies of revision and re-
operations with PKR were also iden tified in an 
observational, registry-based study.19 However, there are 
no comparable data on revisions from ran domised trials 
to-date. Although registry and cohort data can provide 
useful information, to provide further robust and 
unbiased estimates to compare the procedures, a large 
randomised trial was required.
The primary objective for the Total or Partial Knee 
Arthroplasty Trial (TOPKAT) was, therefore, to assess 
the clinical effectiveness and cost-effectiveness of TKR 
versus PKR in patients with medial compartment osteo-
arthritis of the knee in a formal, randomised controlled 
comparison. Secondary objectives included investigation 
of complications (including re-operations and revisions), 
patient satisfaction, and the cost implications of the 
knee replacements for patients, employers, and health-
care providers. This assessment represents the main 
Research in context
Evidence before this study
The evidence to guide choice in the type of arthroplasty used 
for late-stage isolated medial compartment knee arthritis is 
extremely poor. Our study began in 2009, and we searched all 
major databases (MEDLINE, Embase, and PubMed). 
We searched the medical literature for related studies between 
Jan 1, 1990, and Dec 31, 2008, with the search terms “total”, 
“partial”, “unicompartmental”, “knee replacement”, 
“knee arthroplasty”, “trial”, and “outcome” and no language 
restrictions. Before 2009, only cohort studies, indirect 
comparisons, and retrospective studies had been undertaken, 
which aimed to address specific aspects of each operation, 
and no large, well powered, multicentre randomised 
comparative controlled trials had been done. However, 
two small randomised trials had been done, both in the UK. 
The Knee Arthroplasty Trial had a component comparing partial 
knee replacement (PKR) with total knee replacement (TKR) but 
this comparison had to be terminated early because of 
inadequate recruitment. Another small single-centre 
randomised controlled trial that was published in 1998 (5 years 
after starting) and followed up in 2009 (after 15 years) reported 
good long-term follow-up, and the trial showed benefits of 
PKR; however, the study was underpowered for both knee score 
and revision frequency. Since 2009, three new randomised 
controlled trials have been published, but these trials were also 
small single-centre studies (comprising 56–72 participants per 
trial). To our knowledge, there are five ongoing trials. 
Additionally, a propensity-matched cohort study from the 
National Joint Registry was published in The Lancet in 2014, 
but the focus was solely on adverse outcomes (namely, revision 
frequency—described in terms of implant survival—and death). 
In this time, two systematic reviews with meta-analyses have 
also been published, both of which confirmed that there are 
minimal randomised trial data on which to guide treatment, 
and there are no robust randomised trials reporting outcomes 
in the longer term (ie, beyond 5 years).
Added value of this study
Our addition of the first large multicentre randomised study 
provides the best quality evidence to date to guide knee 
replacement treatment globally, and these data show low 
concordance with well established registry and cohort data. 
Our results after 5 years regarding the number of re-operations 
and revisions do not correspond to joint registry data, in which 
PKR has been shown to lead to more revisions than TKR. 
Also, our health economic data, which had previously not been 
assessed to this level of detail, adds an additional dimension 
and further weight to our overall interpretation and guidance 
for practice. Our trial reflects the breadth of current practice 
through the inclusion of all types of implants, which is a 
strength, and its funding source (namely, our dissociation from 
industry, in a context of commonplace industry-supported 
research on surgical devices) helps to ensure unbiased evidence. 
Implications of all the available evidence
Knee replacement is increasing in frequency, and it has an 
associated substantial cost implication to any health-care 
provider. It is also essential that patients receive the most 
efficacious operation for this condition. Before our study, 
and despite several cohort-based reports, knowledge of whether 
one operation type is superior, remained uncertain. Our 5-year 
study has indicated that both TKR and PKR are beneficial 
interventions but, based on our combined clinical and 
cost-effectiveness data and providing the operation is performed 
by those with adequate experience, we recommend that PKR 
should be offered as the treatment of choice for late-stage 
isolated medial compartment osteoarthritis of the knee.
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endpoint results after 5 years of a 10-year follow-up 
study. 
Methods
Study design and participants
The detailed study design and protocol have previously 
been published.20 In summary, TOPKAT was a multicentre, 
pragmatic randomised controlled trial of patients with 
isolated medial compartmental osteoarthritis who were 
randomly assigned to receive either PKR or TKR. The 
trial had a combined expertise-based and equipoise-based 
approach. The expertise-based randomisation21 enabled 
surgeons who were not in the equipoise group to work in 
pairs, and each surgeon (as experts in a specific operation 
type) agreed to perform the operation type that they felt 
was appropriate (giving one surgeon in the pair who used 
TKR and one who used PKR); patients were then ran-
domly assigned to a TKR or PKR surgeon in the pairs. The 
equipoise-based randomisation involved surgeons in the 
equipoise group who had sufficient experience of both 
operation types to perform either operation (PKR or TKR) 
without compromise. Minimum levels of expertise were 
ensured to participate in the trial. PKR-only and TKR-only 
surgeons were required to have had appropriate training, 
to have been practising their technique for at least 1 year, 
and to have performed their operation at least ten times in 
the previous year. Equipoise surgeons, who delivered 
both operations, were required to satisfy the criteria for 
both operations—ie, they had appropriate training in both 
operations and had performed a minimum of ten PKR and 
ten TKR procedures in the previous year.
We recruited patients from 27 sites across the UK (and 
68 surgeons at these sites). Potential participants were 
identified in outpatient and pre-assessment clinics by 
participating surgeons. For study inclusion, partici-
pants had to have isolated osteoarthritis of the medial 
compartment of the knee and to satisfy general require-
ments for a medial PKR. Detailed inclusion and exclusion 
criteria are provided in the published protocol.20 Patients 
who required simul taneous bilateral knee replacement 
were excluded. Participants signed a consent form during 
their screening visit, and they were free to withdraw from 
the study at any time without affecting their routine 
perioperative care. The study obtained approval from the 
UK National Research Ethics Service (Research Ethics 
Committee South Central Oxford C) in September, 2009 
(09/H0606/88).
Randomisation and masking
Participants were randomly assigned (1:1) to receive TKR 
or PKR. For the randomisation procedure (in which we 
also used minimisation), we used a web-based random-
isation service at the Centre for Healthcare Randomised 
Trials (Health Services Research Unit, University of 
Aberdeen, UK). We also used a minimisation algorithm 
that incorporated sex, age band (<50, 50–70, or >70 years), 
baseline Oxford Knee Score (OKS) band (14 or less, 15–21, 
or 22 or more), and delivery unit. A delivery unit was 
either an equipoise surgeon or a pair of expertise surgeons 
with complementary expertise.20 Surgeons, patients, and 
follow-up assessors were not masked to allocation, but the 
implant type was not highlighted at any stage.
Procedures
Our trial compared the TKR procedure versus the PKR 
procedure rather than a specific brand of TKR implant 
versus a specific brand of PKR implant. As such, 
surgeons were free to use the implant of their own 
choice, or that of their institution. A TKR involves all 
surfaces of the knee being replaced. The procedure 
involves excising both diseased and normal femoral 
condyles, the tibial plateau—and often the patella—and 
removing or releasing some of the ligaments. The 
artificial implant can be cemented in position. A PKR or 
unicompartmental knee replacement involves only the 
diseased area of the joint being replaced by artificial 
implants, whereas healthy compartments of the knee 
and ligaments are retained.
The baseline assessment included a patient self-reported 
questionnaire to examine the frequency and intensity 
of knee pain and knee function (measured by the OKS), 
activity, health-care resource use, and the American Knee 
Society Score.22 Routine pre-operative X-rays were also 
used.
We recorded operative details in theatre, and we 
routinely took postoperative X-rays. Patients attended a 
clinic for an American Knee Society Score assessment 
and a complication review 2 months, 1 year, and 5 years 
after their operation. All other outcomes were collected 
with postal questionnaires at 2 months after the operation 
and 1 year after randomisation and, thereafter, annually 
(until 5 years after randomisation).
We collected data on complications and re-operation 
from various sources for cross-referencing and to ensure 
completeness. Complication data were collected from 
participants in their follow-up questionnaires and clinical 
assessment visits. Any reported re-admissions were 
followed up with the patient’s hospital to obtain further 
details. Local research teams did a final check of hospital 
records 5 years after the operations, to ensure that 
complications data were collected from all participants 
(ie, those who had not returned a questionnaire or 
attended a follow-up visit).
Outcomes
The primary outcome measure was the OKS 5 years after 
randomisation in all patients assigned to groups. The 
OKS is a patient self-reported outcome questionnaire that 
was specifically developed to assess function and pain 
after knee replacement surgery. This score is a validated 
and responsive measure of knee function and related 
pain.23,24
The secondary outcome measures were assessed at 
5 years after randomisation in all patients assigned to 
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receive an operation. These outcomes were the American 
Knee Society Score,22 the University of California, 
Los Angeles Activity Score,25 the High Activity Arthroplasty 
Score,26 the EuroQol EQ-5D-3L,27 the Lund Satisfaction 
Score,28 the frequency of complications (determining the 
number of patients who required re-admission and a 
re-operation), and three patient-reported anchor type 
questions regarding satisfaction, a comparison of prob-
lems with their knee before versus after the surgery, 
and whether they would have the operation again. 
The response categories are shown in the appendix (p 1). 
We also assessed a composite outcome for failure (a 
combination of re-operation and poor outcomes, as 
determined by an improvement in OKS of less than 
four points). This composite outcome assessment has 
not been validated and it is therefore considered an 
exploratory outcome.
Length of hospital stay and data on use of health-care 
services were collected for an health economics analysis.
Statistical analysis
A necessary sample size was calculated for the OKS 
and the incidence of re-operations. Our trial was 
powered to detect a 2·0-point difference in OKS with 
80% power (or, equivalently, 90% power to detect a 
3·0-point change) at a 5% (two-sided) significance level 
with an SD of 10·0 points. For this power, a sample 
size of 500 patients was required.29,30 The sample size 
was adequate to detect a change in incidence of re-
operations of 7% between groups (from 5% to 12%) at 
80% power. Of note, a study31 done and published 
after the TOPKAT trial was planned suggested that a 
5-point difference in OKS should become the appro-
priate minimally important difference in OKS.
Full details of the statistical analyses are contained 
in the statistical analysis plan (available on request). 
In brief, the statistical analysis was primarily on an 
intention-to-treat basis and used all available participant 
data. The OKS scores at 5 years, which were compared 
with a linear regression analysis, were adjusted for 
minimisation factors and baseline OKS, and a cluster 
robust error was added for surgery delivery unit. A 
differential effect of expertise versus equipoise delivery of 
the intervention on treatment effect was explored with an 
interaction effect. The incidence of compli cations and re-
operations, including revisions, and other binary variables 
were compared with Poisson regression, to estimate risk 
ratio, and they were adjusted for minimisation covariates 
and a cluster robust error for surgeon delivery unit. We 
used prespecified secondary analyses (unadjusted t test, 
a multi level model to assess the marginal difference) 
and subgroup analyses (sex, OKS band, and age band, 
evaluated with treatment-by-subgroup interactions). To 
assess the effect of compliance (the operation being 
delivered as intended), an instrumental variable method 
was used to estimate the complier-average causal effect 
at 5 years after randomisation. We also performed a 
post-hoc analysis of OKS that used the area under the 
curve (AUC), generated for each participant with the 
trapezoidal rule, to describe the effects of TKR and PKR 
on OKS across all available timepoints.
Statistical significance was judged at the two-sided 
5% level and treatment effect estimates are presented 
with corresponding 95% CIs. Low frequency event data, 
such as re-operations and revisions, were also analysed 
on an as-treated basis, to avoid misrepresentation from 
incompliance to the allocated intervention (ie, crossovers).
We also did a within-trial cost-effectiveness analysis. 
Total costs and quality-adjusted life-years (QALYs) for 
all 528 participants were estimated from the date of 
recruitment until the earliest of death, withdrawal from 
Figure 1: Trial profile
The 5-year intention-to-treat analysis includes only patients who provided results for the Oxford Knee Score 
assessment. PKR=partial knee replacement. TKR=total knee replacement.
264 assigned to receive TKR 
and completed baseline 
assessment
 
238 received TKR
264 assessed at 5-year 
follow-up
 232 responded to 
questionnaire
 11 did not respond
 11 died
10 withdrawn
 
231 included in 5-year
intention-to-treat 
analysis of primary 
outcome 
 196 attended a clinical 
assessment
26 did not receive TKR
 13 received PKR
 4 withdrawn before 
surgery
 8 did not receive surgery
 1 died before surgery
962 patients assessed for eligibility
 
531 enrolled and randomly assigned
431 ineligible
 121 did not meet inclusion criteria
 310 declined participation
3 randomised twice, so excluded
 2 from PKR group
 1 from TKR group
264 assigned to receive PKR 
 and completed baseline 
 assessment
 
232 received PKR
264 assessed at 5-year 
follow-up
 235 responded to 
questionnaire
 18 did not respond
 6 died
 5 withdrawn
233 included in 5-year 
intention-to-treat 
analysis of primary 
outcome 
201 attended a clinical 
assessment
32 did not receive PKR
 31 received TKR
 1 withdrawn before 
surgery
See Online for appendix
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study, or the end of follow-up at 5 years. Both costs 
and QALYs were discounted at 3·5% per year. Missing 
data on EQ-5D score and health-care costs were imputed 
with multiple imputation by chained equations, assum-
ing data was missing at random (since there was no 
evidence that the probability that data was missing 
depended on baseline participant characteristics or on 
lagged outcomes).32 Ten imputed datasets were created 
with predictive mean matching. Imputation was 
performed separately by treatment allocation. After 
imputation, the mean total health-care costs and QALYs 
were estimated with separate linear regression models 
controlling for treatment allocation, age band, sex, and 
baseline OKS band, following the main clinical analysis. 
For QALYs we additionally controlled for EQ-5D score at 
baseline. The incremental cost-effectiveness ratio was 
calculated by dividing the mean cost difference between 
PKR and TKR by the mean QALY difference. The joint 
PKR (n=264) TKR (n=264)
Age, years 65·2 (8·8) 64·7 (8·5)
Sex
Male 153 (58%) 153 (58%)
Female 111 (42%) 111 (42%)
Study knee
Left 140 (53%) 141 (53%)
Right 124 (47%) 123 (47%)
Duration of osteoarthritis
<3 years 75 (28%) 73 (28%)
3–5 years 82 (31%) 72 (27%)
6–10 years 59 (22%) 73 (28%)
>10 years 36 (14%) 30 (11%)
Missing data 12 (5%) 16 (6%)
Medical history of conditions
Other joint problems 106 (40%) 96 (36%)
Cardiovascular 80 (30%) 86 (33%)
Diabetes 27 (10%) 26 (10%)
Gastrointestinal 17 (6%) 18 (7%)
Respiratory 19 (7%) 12 (5%)
Cancer 6 (2%) 8 (3%)
Renal or urological 8 (3%) 8 (3%)
Neurological 7 (3%) 6 (2%)
Mental health 7 (3%) 6 (2%)
Thyroid problems 3 (1%) 2 (1%)
Other* 5 (2%) 4 (2%)
Employment status
Retired 159 (60%) 162 (61%)
Unemployed 15 (6%) 21 (8%)
Employed 82 (31%) 73 (28%)
Missing data 8 (3%) 8 (3%)
Body-mass index (n=210 vs n=221) 31·0 (4·6) 31·1 (4·8)
Extent of knee arthritis affecting mobility (Charnley ABC)
Single 99 (38%) 119 (45%)
Both 142 (54%) 121 (46%)
Multiple arthritis or medical 
infirmity
6 (2%) 11 (4%)
Missing data 17 (6%) 13 (5%)
General health (n=259 vs n=260) 2·6 (0·9) 2·8 (0·9)
General health relative to 1 year 
ago (n=259 vs n=260)
3·3 (0·8) 3·3 (0·8)
(Table 1 continues in next column)
PKR (n=264) TKR (n=264)
(Continued from previous column)
Previous treatment on study knee
Analgesia 207 (78%) 184 (70%)
Arthroscopy 44 (17%) 47 (18%)
Arthroscopic investigative 
washout or debridement
44 (17%) 36 (14%)
Open or arthroscopic meniscus 33 (13%) 30 (11%)
Knee injection with steroids 19 (7%) 21 (8%)
Knee injection with viscosupp 2 (1%) 3 (1%)
Knee injection (type not stated) 4 (2%) 6 (2%)
Acupuncture 4 (2%) 5 (2%)
Chiropractor or osteopath 1 (<1%) 3 (1%)
Cartilage implantation 1 (<1%) 2 (1%)
Anterior cruciate ligament 
repair
1 (<1%) 0
Other† 0 3 (1%)
None 13 (5%) 26 (10%)
Problems with the other knee
None 86 (33%) 99 (38%)
Mild 93 (35%) 74 (28%)
Moderate 63 (24%) 52 (20%)
Severe 18 (7%) 30 (11%)
Missing data 4 (2%) 9 (3%)
Contralateral knee
TKR 24 (9%) 14 (5%)
PKR 16 (6%) 16 (6%)
Unsure 1 (<1%) 1 (<1%)
None 208 (79%) 217 (82%)
Missing 15 (6%) 16 (6%)
Oxford Knee Score 18·8 (7·0) 19·0 (7·2)
High Activity Arthroplasty Score 
(n=258 vs n=256)
4·8 (2·3) 4·6 (2·3)
University of California, 
Los Angeles Activity score 
(n=260 vs n=260)
3·6 (1·5) 3·7 (1·5)
American Knee Society score 
(objective; n=260 vs n=259)
41·0 (16·1) 42·3 (16·0)
American Knee Society score 
(functional; n=262 vs n=259)
59·3 (15·6) 58·7 (15·5)
EQ-5D-3L score (n=257 vs n=252) 0·428 (0·301) 0·381 (0·324)
EQ-5D visual analogue score 
(n=249 vs n=257)
62·8 (27·0) 60·7 (28·7)
Data are mean (SD) or n (%), unless otherwise indicated. PKR=partial knee 
replacement. TKR=total knee replacement. EQ-5D-3L=EuroQol (five dimensions, 
three levels). *Includes high body-mass index (PKR n=1; TKR n=1), antiphospholipid 
syndrome (TKR n=1), glaucoma (PKR n=1), cataracts (TKR n=1), anaemia (PKR n=2), 
appendicectomy (TKR n=1), and lipoma of intra-abdominal organs (PKR n=1). 
†Includes laser treatment (n=1), offloader knee brace (n=1), and aspiration (n=1).
Table 1: Baseline characteristics
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uncertainty around incremental total costs and QALYs 
(ie, the diff erence between PKR and TKR), and in the 
cost-effectiveness, was also investigated. All statistical 
analyses were done with Stata version 15, and all health 
economic analyses were done with R version 3.4.3.
A summary of the results, masked for implant iden-
tifier, was sent to five separate independent reviewers 
(experts who were familiar with orthopaedics, or trial 
design or interpretation, or both) plus the trial steering 
committee chair, to obtain an unbiased interpretation 
and conclusion of the trial. Any TOPKAT team members 
with strong personal opinions or conflicts of interest, 
although helpful in the setting up of the study, had little 
or no part in the conduct of the study or interpretation 
of the results. This trial is registered with ISRCTN, 
(ISRCTN03013488) and ClinicalTrials.gov (NCT01352247).
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
Between Jan 18, 2010, and Sept 30, 2013, we recruited 
patients from 27 sites across the UK, and we included 
68 surgeons from these sites. We assessed 962 patients 
for their eligi bility, of whom 431 (45%) patients were 
excluded (121 [13%] patients did not meet the inclusion 
criteria and 310 [32%] patients declined to participate) 
and 528 (55%) patients were randomly assigned to 
groups (figure 1). Three patients were randomly assigned 
to groups twice in error, and the second randomisation 
was treated as a post-randomisation exclusion. Of the 
528 patients, 264 (50%) patients were assigned to the 
PKR group, of whom 233 (88%) patients provided results 
for assessment of the primary outcome, and 264 (50%) 
patients were assigned to the TKR group, of whom 
231 (88%) patients provided results for assessment of the 
primary outcome. 
44 participants had a knee replacement but did not 
receive their allocated device (crossovers). 31 (12%) patients 
allocated to PKR received TKR: in six (19%) patients, 
the crossover occurred before surgery (the osteoarthritis 
pattern was not suitable for PKR [n=2]; patient 
decision [n=1]; inflammatory arthropathy [not suitable for 
PKR; n=1]; after random allocation to groups, the patient 
was deemed not suitable for PKR because of a 
contraindication [n=1]; and because of an error in 
communication of group allocation at the site [n=1]); and 
in 25 (81%) patients, an intra-operative conversion was 
made (the osteoarthritis pattern was not suitable for PKR 
[n=20]; and the anterior cruciate ligament was found to be 
absent or deteriorated [n=5]). 13 (5%) patients who were 
allocated to TKR received PKR: in eight (62%) patients, the 
crossover occurred before surgery (patient decision [n=5]; 
and error in communication of randomisation allocation 
at site [n=3]); and in five (38%) patients, an intra-operative 
decision was made (independent surgeon decision—ie, all 
eligibility criteria met but decision made to use PKR). The 
groups were well balanced on all baseline characteristics 
(table 1). The types of implants used in the study reflected 
current practice (appendix p 2).
The operation time was similar in both groups, at 
around 70 min (PKR mean duration 69 min [SD 18]; 
TKR 70 min [22]; appendix p 15). The length of the hos-
pital stay for the surgery differed significantly between 
Figure 2: Oxford Knee Scores after randomisation
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5 years 38·0 (10·1) 233 37·0 (10·6) 231 1·04 (–0·42 to 2·50) 0·159
EQ-5D-3L score
Baseline 0·428 (0·30) 257 0·381 (0·32) 252 1 (ref) ··
5 years 0·744 (0·29) 224 0·717 (0·32) 212 0·018 (–0·033 to 0·069) 0·48
EQ-5D visual analogue scale score
Baseline 62·8 (27·0) 249 60·7 (28·7) 257 1 (ref) ··
5 years 75·4 (16·5) 228 71·7 (19·7) 217 4·02 (1·36 to 6·67) 0·004
High Activity Arthroplasty Score
Baseline 4·8 (2·3) 258 4·6 (2·3) 256 1 (ref) ··
5 years 7·9 (3·5) 218 7·6 (3·4) 207 0·22 (–0·24 to 0·67) 0·33
University of California, Los Angeles Activity score
Baseline 3·6 (1·5) 260 3·7 (1·5) 260 1 (ref) ··
5 years 5·0 (1·9) 221 4·9 (2·0) 215 0·17 (–0·09 to 0·43) 0·19
American Knee Society score (objective)
Baseline 41·0 (16·1) 260 42·3 (16·0) 259 1 (ref) ··
5 years 85·8 (16·6) 191 86·6 (16·4) 185 –0·89 (–5·18 to 3·41) 0·68
American Knee Society score (functional)
Baseline 59·3 (15·6) 262 58·7 (15·5) 259 1 (ref) ··
5 years 82·6 (18·5) 195 81·7 (19·0) 192 0·37 (–3·81 to 4·55) 0·86
EQ-5D-3L=EuroQol (five dimensions, three levels).
Table 2: Estimated treatment effect on primary and secondary outcomes, at baseline and at 5 years
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groups: those receiving PKR stayed for a mean duration 
of 3·2 days (1·3), and those receiving TKR stayed for a 
mean duration of 4·3 days (3·6; risk ratio [RR] 0·74, 
95% CI 0·63 to 0·87; p <0·0001). 5 years after ran-
domisation, 94% of patients responded to the follow-up 
question naire (88% for the primary outcome; PKR 
n=233, TKR n=231). Patients in both groups had superior 
outcomes relative to their preoperative baseline status. 
OKS had substantially changed in both groups: we found 
a mean change in OKS of more than 18 points for both 
procedures.
At the 5-year follow-up, we found no difference in 
OKS between groups (mean difference 1·04, 95% CI 
–0·42 to 2·50; p=0·159; table 2; figure 2). After 5 years, 
the EQ-5D visual analogue scale score was better in 
those who received PKR than those who received TKR 
(4·02, 1·36 to 6·67; p=0·004). However, we found no 
differences in the other secondary outcome scores at 
5 years. Patient satisfaction after 5 years did not differ 
between the groups (190 [82%] of 233 patients receiving 
PKR vs 173 [77%] of 225 patients receiving TKR; RR 1·06, 
95% CI 0·99 to 1·13; p=0·097; table 3). However, 
we found differences at 5 years in the results of the 
two questions asking about whether the patient’s knee 
was better to before their operation (219 [95%] of 
230 PKR patients vs 200 [90%] of 222 TKR patients; 1·06, 
1·01 to 1·11; p=0·016) and whether the patient would 
have the operation again (208 [91%] of 228 patients vs 
183 [84%] of 217 patients; 1·08, 1·02 to 1·15; p=0·010). 
At the 5-year analysis, OKS did not differ between the 
surgeon groupings (ie, expertise pair vs equipoise 
surgeons; interaction effect –1·31, 95% CI –5·34 to 2·73; 
p=0·518), nor between the age band, sex, or OKS band 
subgroups (appendix p 14). At 5 years, there was also no 
effect of surgeon experience, as defined by the number 
of procedures of each operation type performed by the 
surgeons before the study (appendix p 11).
Patients receiving TKR had more complications than 
those receiving PKR (73 [27%] of 269 patients vs 48 [20%] 
of 245 patients; RR 0·72, 95% CI 0·53–0·98; p=0·036; 
appendix pp 4–6). The most common compli cations 
were unexplained pain (nine patients receiving PKR vs 
eight patients receiving TKR), knee stiffness (0 patients 
vs ten patients) and both unexplained pain and knee 
stiffness together (one patient vs six patients). The 
number of re-operations and revisions were similar 
between groups (table 4). Of those who had surgery (ie, 
as treated), 15 (6%) of 245 patients receiving PKR had a 
re-operation and 21 (8%) of 269 patients receiving TKR 
had a re-operation (0·75, 0·37–1·53; p=0·432). After both 
surgeries, ten (4%) patients had revisions, pre dominantly 
because of unexplained pain (two patients receiving PKR 
vs five patients receiving TKR) or bearing dislocation 
(three patients vs 0 patients). When we analysed the 
revision and complication results with intention-to-treat 
(ie, as allocated) data, we found similar results to those of 
the as-treated analyses. There were 28 failures of PKR and 
38 failures of TKR, as defined by the composite outcome, 
which was a non-significant difference (0·74, 0·51–1·08; 
p=0·118). During the 5-year follow-up, 17 deaths were 
reported: six (2%) deaths in the PKR group and 11 (4%) 
deaths in the TKR group (appendix p 12). These deaths 
were predominantly due to cancer (four deaths in the 
PKR group vs six deaths in the TKR group) and there 
were two deaths in each group for unknown reasons.
Partial knee 
replacement
Total knee 
replacement
Risk ratio (95% CI) p value
n (%) Valid N n (%) Valid N
Satisfied with knee 190 (82%) 233 173 (77%) 225 1·06 (0·99–1·13) 0·097
Knee better or worse, 
now versus before 
surgery
219 (95%) 230 200 (90%) 222 1·06 (1·01–1·11) 0·016
Would choose to have 
knee operation again
208 (91%) 228 183 (84%) 217 1·08 (1·02–1·15) 0·010
Valid N data are the number who responded to the question.
Table 3: Estimated treatment effect on self-reported anchor questions at 5 years
Treatment received Treatment as allocated
PKR (n=245) TKR (n=269) PKR (n=263) TKR (n=251)
Number of participants receiving a 
re-operation
15 (6%) 21 (8%) 14 (5%) 22 (9%)
Number of re-operations 22 (9%) 28 (10%) 18 (7%) 32 (13%)
Number of participants with revision 10 (4%) 10 (4%) 8 (3%) 12 (5%)
Unexplained pain 2 5 1 6
Bearing dislocation 3 0 3 0
Device loosening (tibia) 2 0 1 1
Bearing dislocation and unexplained 
pain
1 0 1 0
Ligamentous instability 1 0 1 0
Infection 1 0 1 0
Infection and mechanical failure 0 1 0 1
Knee stiffness and unexplained pain 0 1 0 1
Ligamentous instability and 
malalignment
0 1 0 1
Unknown 0 2 0 2
Number of other procedures 12 18 10 20
MUA 0 12 1 11
Aspiration 3 2 3 2
Arthroscopy 3 0 3 0
Arthroscopy and debridement or 
washout
1 1 1 1
Debridement, exploration, or 
washout
2 0 0 2
Open reduction and internal fixation 1 0 1 0
Marcaine injection and MUA 2 0 1 1
Arthroscopy and MUA 0 1 0 1
Arthroscopy and biopsy 0 1 0 1
Arthroscopy and partial medial 
meniscectomy
0 1 0 1
Data are n or n (%). PKR=partial knee replacement. TKR=total knee replacement. MUA=manipulation under anaesthetic.
Table 4: Number of re-operations, including revisions, by treatment received and as allocated at 5 years
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In our within-trial cost-effectiveness analysis, we 
found that PKR was more effective (0·240 additional 
QALYs, 95% CI 0·046 to 0·434) and less expensive than 
TKR (–£910, 95% CI –1503 to –317) during the 5 years of 
follow-up (figure 3). The probability that PKR was the 
most cost-effective option was more than 99·9% for all 
reasonable threshold values. This finding was a result of 
better outcome, as measured by QALYs derived from 
EQ-5D scores (appendix p 7) and survival, lower costs of 
PKR surgery, and lower follow-up health-care costs with 
PKR than TKR. Even assuming equal costs of the 
implant device, PKR was less costly and more effective 
than TKR. The proportion of missing data imputed to 
inform the cost-effectiveness analysis was 12% per 
period, on average (appendix p 8). Index surgery costs 
and cost effectiveness comparisons are given in the 
appendix (pp 9–10).
The planned secondary analysis of the unadjusted 
OKS showed similar results to the primary outcome 
analysis, as did a marginal estimate over the whole 
5-year follow-up (mean difference 1·39, 95% CI 
–0·12 to 2·90; p=0·071). The complier-average causal 
effect analysis at 5 years showed no difference (0·86, 
–0·62 to 2·34; p=0·254). The AUC of the OKS across 
the whole study period signifi cantly favoured PKR 
versus TKR. The mean AUC was 36·6 (SD 8·3) for 
233 participants in the PKR group and 35·1 (9·1) for 
the 231 participants in the TKR group (mean difference 
1·54, 95% CI 0·07 to 3·01; p=0·040); notably, this 
difference is smaller than the revised estimated minimal 
important difference31 of 5 OKS points. A kernel density 
plot for OKS at baseline and 5 years is shown in the 
appendix (p 13). 
Discussion
To our knowledge, our study is the largest multicentre 
randomised trial to compare TKR with PKR, and it 
provides the most robust evidence to date on the 
comparative effectiveness of the two approaches for the 
management of medial compartmental osteoarthritis. 
Our trial has high generalisability, since it involves many 
surgeons from several centres across the UK, and the 
hybrid design uniquely includes surgeons both in and 
out of equipoise, which allowed them to perform the 
surgery of their stated preference and expertise.
We found that both interventions (PKR and TKR) 
provided medium-term benefits for patients with medial 
compartment osteoarthritis by producing substantial 
changes in outcomes (more than 18 OKS points with both 
surgeries). Despite no differences in the primary out-
come (on cross-sectional analysis), there was consistent 
evidence overall to suggest a modest clinical benefit of 
PKR over TKR. The analysis of the OKS AUC and patient-
directed questions about patient satisfaction, perceived 
change in their knee problem, and willingness to choose 
to have the operation again all support this position. 
The duration of hospital stay was also lower with PKR.
Despite low power, we observed no differences between 
the number of re-operations and revisions between 
the trial groups. By contrast, nearly all global registries 
(which comprise non-randomised, observational data) 
report that PKR results in a substantially larger number 
of revisions than TKR (usually more than 6%).17,19 In 
TOPKAT, the frequency of complications was also 
observed to be increased in the TKR group. Although 
interpretation of these event findings in each study type 
is not straightforward, it is likely that non-randomised 
cohort data, despite matching, remain susceptible to 
selection bias (specific patients chosen for a particular 
implant). The difference might also reflect a lower 
threshold for revision of PKR outside of a controlled trial. 
However, Hawthorne-type effects and self-selection of 
the involved surgeons in the trial also cannot be excluded 
as reasoning for the lower frequency of revisions found 
with PKR in TOPKAT relative to other studies. It is 
important to emphasise that the revision and re-operation 
data are more susceptible to bias than some of the 
other variables. The sample size calculations were 
adequate to detect a change in the proportion of overall 
re-operations of 7% between groups (from 5% to 12%) 
with 80% power, and they might therefore be under-
powered to provide concrete evidence on revisions. 
The anticipated differences for the power calculation 
were much larger than the differences in the revision 
frequencies found in our study. Furthermore, differences 
in the number of revisions between subgroups (eg, male 
vs female) would also remain undetected with the sample 
size that we used. Some of our most notable findings 
were in relation to the health economics data. During 
5 years of follow-up in the TOPKAT trial, PKR was found 
Figure 3: Cost-effectiveness of the base-case analysis versus an assumption of equal implant device costs
Large black dots are the mean values for each scenario. 
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to be more effective but also less costly than TKR. Lower 
costs with PKR were a result of lower costs of the index 
surgery (even when assuming equal device costs) and 
lower subsequent use of health-care services, especially 
due to fewer outpatient visits in the first 2 years after the 
index surgery. These data will have most relevance for 
the UK health-care system, but the findings are likely 
to be generalisable to settings with similar health-care 
systems.
There are many general strengths of this study. 
Globally, to our knowledge, our study is the largest, most 
complete, and longest randomised follow-up of any 
comparison of TKR versus PKR to date. Our study was 
well powered and any type 2 errors are highly unlikely. 
The external validity is high, and the pragmatic design 
lends itself to policy support or commissioning changes. 
The follow-up response to the questionnaires was very 
high (94% for all; 88% for the primary outcome). Our 
study included an expertise design, which accounted for 
surgeons who were not in the equipoise group. Our trial 
is unique in that it can provide strong empirical evidence 
to compare with large database studies evaluating TKR 
and PKR, and it could highlight the limitations of relying 
on cohort or non-randomised systematically collected 
data alone. An important strength is the unbiased and 
independent review of our interpretation.
The weaknesses of the study include the absence of 
masking, some missing data for the health-care resource 
and EQ-5D data (12% across all time periods), and some 
non-compliance. It was not feasible to keep patients 
masked from allocation for 5 years; expectancy bias 
(regarding a higher benefit of PKR) cannot therefore be 
entirely ruled out. The missing data was equal between 
groups, and it was found to have no effect on results; no 
imputation method was required for the clinical analysis 
but one was used for the health economics analysis. 
Some non-compliance with allocation (ie, conversion 
from PKR to TKR from operative findings) was 
anticipated and clinically understandable but a complier-
average causal effects analysis that we used to assess 
the potential effects of non-compliance on outcomes did 
not find any issue. The number of participants who 
completed follow-up was just less than the power 
calculation of the target of 500 participants, and this 
disparity is therefore unlikely to affect the results, 
particularly since the main analyses benefited from 
greater precision (not accounted for in the original 
sample size) because of adjustment for minimisation 
variables and, where relevant, also the baseline score. It 
is also acknowledged that the 5-year timeframe prompts 
some limitations. First, the within-trial cost-effectiveness 
analysis was not designed to accommodate for the 
economic implications of potential future revisions; thus 
the longer term implications of any potential future 
changes in the revision profile have not been accounted 
for. Second, patients in both groups are expecting the 
effects of their knee surgery to last longer than 5 years, 
so major differences that occur later will also remain 
undetected. However, a 10-year follow-up has commenced 
and will provide a clearer picture on these data.
The magnitude of the difference observed in the pri-
mary outcome lies within the acknowledged minimally 
important difference in OKS at the time of study 
planning (a 2-point difference), although the 95% CI 
did not rule out the possibility that the effect of PKR 
could exceed 2 points. Irrespective, the observed 
difference is well within the more recently accepted 
minimally important difference in OKS (now set at 
5 points).31 This scale of difference in OKS is unlikely to 
have any discernible impact on national or international 
practice by itself, but clinicians and patients themselves 
must decide whether these small magnitudes of 
difference, and the evidence from other variables, is 
sufficient to modify or support their own individual 
decision making. A kernel density analysis (appendix 
p 13) showed that there were more patients with OKS 
outcome scores of 40 and above in the PKR group than in 
the TKR group, but this finding was balanced by a greater 
number of TKR patients with mid-range scores. Hence, 
there is disagreement as to whether these data imply an 
important clinical signal for efficacy or a more contrived 
outcome to demonstrate differences. The re-operation 
and revision data are of note, suggesting that neither 
operation is associated with a high fre quency of revision, 
a finding in contrast with previous reports that used 
cohort databases. The cost-effectiveness findings are 
undoubtedly the strongest marker, and they suggest that 
PKR is superior in a health-care provision context.
Both TKR and PKR remain treatment options for late-
stage medial compartment arthritis of the knee. PKR 
should, however, be considered the first-choice procedure 
(based on 5-year outcomes). That said, the operation 
should only be done by those surgeons with sufficient 
experience and expertise.
Both TKR and PKR are effective, offer similar clinical 
outcomes, and result in similar frequencies of re-
operations and complications. The number of revisions 
after PKR in our randomised trial were substantially 
lower than found in other, mainly non-randomised, 
cohort data. Assessments focusing on whether the 
patients’ knees felt better after the surgery and whether 
they would have the surgery again were better with PKR. 
And, of note, PKR was more cost-effective than TKR after 
5 years. Although TKR provides good outcomes, based 
on the combined 5-year cost-effectiveness and clinical 
data, PKR should likely be considered the first choice for 
patients with late-stage isolated medial compartment 
osteoarthritis.
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